“…Well-known examples of these effects include the accumulation and the prolonged duration of action of the muscle-relaxant drugs succynylcholine (Fisher et al, 1988;Staun et al, 1990), suxamethonium (Bang et al, 1990), and mivacurium (Ostergaard et al, 2000) observed in patients under BMB medication. BMB, which contains a chiral center, is currently synthesized and administered as a racemate, but there is some evidence that the (R)-enantiomer is more potent and less toxic than its mirror image (Morley, 2002;Tan and Cheng, 2009). On this basis, (R)-BMB hydrochloride has been recently approved by the Chinese State Food and Drug Administration for phase I clinical trials, and a preliminary pharmacokinetic study has been published (Zhou et al, 2014a).…”